Intravenous (IV) ibuprofen is an injectable pharmaceutical formulation of ibuprofen used for the treatment of pain, fever, and inflammation. IV ibuprofen provides rapid administration of ibuprofen through intravenous route and overcomes the limitations of oral administration in critically-ill patients. It is used for indications such as post-operative pain, dental pain, musculoskeletal pain, and fever. The demand for IV ibuprofen is increasing globally as it offers several advantages over other intravenous opioids and non-steroidal anti-inflammatory drugs including reduced length of hospital stay and lower rates of adverse drug reactions.

Global intravenous (IV) ibuprofen market is estimated to be valued at USD 6.91 Bn in 2024 and is expected to reach USD 11.13 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 7% from 2024 to 2031.

Key Takeaways

Key players operating in the Intravenous (IV) Ibuprofen market are Cumberland Pharmaceuticals Inc., Hyloris Pharmaceuticals SA, Grifols, S.A., Recordati Rare Diseases Inc., XGEN PHARMACEUTICALS DJB, Inc., AFT Pharmaceuticals, Laboratorios Valmorca, SGPharma Pvt. Ltd., Wellona Pharma, Delex Pharma, Hikma Pharmaceuticals PLC.

The market is witnessing increasing opportunities in pediatric applications and management of postsurgical pain. Several companies are investing in clinical trials for new indications to expand their product portfolios.

The demand for IV ibuprofen is growing globally with major pharmaceutical giants focusing on geographic expansion plans across Asia Pacific, Latin America, and Middle East & Africa. These regions offer high growth potential owing to increasing healthcare investments and improving access to specialty drugs.

Market Drivers

The widespread use of Intravenous (IV) Ibuprofen Market Size in postoperative and orthopedic procedures is one of the major factors propelling the market growth. Its efficacy in reducing pain faster compared to opioids and oral NSAIDs is driving its acceptance among healthcare professionals. Also, increasing R&D in cannulating formulations and lyophilized preparations is anticipated to further support the market expansion over the forecast period.

PEST Analysis

Political: Regulations regarding usage of intravenous ibuprofen in different countries: Usage is allowed in countries like US, Canada, EU nations but regulations vary in Asian countries.

Economic: Demand for intravenous pain relievers is expected to rise due to growing elderly population suffering from joint pains, arthritis who prefer fast relief. Rising healthcare spending will also support market growth.

Social: Growing awareness about advantages of IV formulations like fast onset of action and relief compared to oral medications driving preference for IV ibuprofen among patients and doctors.

Technological: Manufacturers are focusing on developing enhanced formulations for improved bioavailability and stability to cater to varying patient needs.

Get More Insights on- Intravenous (IV) Ibuprofen Market

For Deeper Insights, Find the Report in the Language that You want:

• French
• German
• Italian
• Russian
• Japanese
• Chinese
• Korean
• Portuguese